Jubilant Ingrevia Ltd (BOM:543271)

Q3 2026 Jubilant Ingrevia Ltd Earnings Call Transcript

Feb 5, 2026 / 11:30 AM GMT

Release Date Price: ₹625.55 (-4.42%)

Transcript

Key Points

Positve

Jubilant Ingrevia Ltd (BOM:543271) reported stable revenues and margins despite challenging market conditions, driven by incremental sales volumes across all segments.
The company achieved its second highest volumes in the last 12 quarters, with a 9% volume growth during the quarter.
The specialty chemical segment demonstrated resilience with margins above 25%, supported by a favorable product mix and ongoing cost optimization initiatives.
The nutrition and health solutions business delivered volume growth both quarter on quarter and year on year, with the vitamin B3 portfolio reaching its highest volumes in the past 7 quarters.
Jubilant Ingrevia Ltd (BOM:543271) is making significant progress in its CDMO segment, with increased customer traction and a new multi-purpose plant under construction to enhance capacity.

Negative

The company is facing sustained pricing pressure across most segments, impacting overall financial performance.
Elevated energy costs and weaker demand have contributed to deteriorating financial conditions.
The chemical intermediate segment recorded lower realization across key products, leading to a decline in revenue.
Despite volume growth, the nutrition segment experienced a 10% year-on-year decline in EBITDA due to price declines in the vitamin B3 portfolio and choline.
The European market continues to face headwinds with weak demand and plant closures affecting performance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

JUBN.NS - Jubilant Ingrevia Ltd
Q3 2026 Jubilant Ingrevia Ltd Earnings Call
Feb 05, 2026 / 11:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Are reporting deteriorating financial.

Due to weaker demand, sustained pricing pressure, and elevated energy costs, our performance demonstrates resilience and strength in navigating these challenges.

In the pharmaceutical end use market.

Volumes have remained steady across segments.

With particular strength in our core fine chemicals portfolio.

With recent signing of FTAs with the United States and EU.

We are expecting a high degree of engagement and inquiries from customers in coming months.

In the agrochemical sector, we are witnessing a steady recovery in volumes both globally in India.

With pyride based products and the acetyl group showing

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.